Navin Fluorine International reported a stellar Q1 FY27, with net profit rising 108% to Rs 243.31 crore. Revenue grew 44% YoY, driven by strong performances across its HPP, Specialty Chemicals, and CDMO verticals. Operating margins also improved significantly to 34.2%. The company is now focused on executing a massive capex pipeline across its key segments to drive growth through FY28.
Navin Fluorine Q1 Profit Jumps 108% to Rs 243.31 Crore
Net Revenue rose 44% YoY to Rs 1,045.08 crore; Operating EBITDA jumped 73% to Rs 357.07 crore.
Reader Takeaway: Robust growth across all segments and margin expansion face future dependency on timely capex commissioning schedules.
What just happened
Navin Fluorine International (NFIL) delivered a strong financial start to FY27. For the first quarter, the company reported a net profit of Rs 243.31 crore, a 108% increase compared to the same quarter last year. Revenue saw a healthy 44% climb to Rs 1,045.08 crore. Margins were a highlight, with Operating EBITDA margin reaching 34.2%, up 566 basis points year-on-year.
Business Vertical Performance
Growth was broad-based across all three business segments:
- High Performance Products (HPP): Revenue grew 33% to Rs 540 crore, aided by the ramping of the new AHF facility.
- Specialty Chemicals: Revenue rose 48% to Rs 325 crore, driven by strong order books and a healthy pipeline.
- CDMO: The standout performer with 82% growth to Rs 180 crore, bolstered by increased partnership depth with a key European client.
Ongoing Capex Program
The company has an aggressive capital expenditure roadmap intended to bolster capacity throughout FY27. Key projects include a 15,000 MTPA R32 expansion (Rs 236.5 crore), Dahej facility debottlenecking (Rs 75 crore), and the new cGMP4 facility for the CDMO business (Rs 125 crore). Most of these projects are slated for commissioning between Q2 and Q4 of FY27.
What to track next
Investors should monitor the execution of the ongoing capex projects. As the company transitions from the investment phase to operationalizing these assets, the ramp-up speed in the HPP and Chemours-related projects will be critical for sustaining current growth rates and margin profiles.